Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GenuFlex is an oral nutraceutical developed by Parnasa Mediworld, specifically formulated as a sachet containing bioactive collagen peptides for the support of joint health. The product functions by delivering specific peptide fragments that are absorbed and distributed to joint tissues, where they act as signaling molecules to stimulate chondrocytes. This stimulation promotes the biosynthesis of essential extracellular matrix components, including type II collagen and proteoglycans, which are vital for the structural integrity, elasticity, and shock-absorbing properties of articular cartilage. By enhancing cartilage repair and potentially reducing inflammatory markers, GenuFlex is intended to alleviate joint pain and improve mobility in individuals with degenerative joint conditions or age-related wear.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on GenuFlex.